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Objective: Coagulation activation markers are significantly elevated in patients with peripheral arterial disease compared
with healthy controls. The more severe the disease, the higher the markers. Increased coagulation activation may
contribute to the disease process and the risk of complications in patients with peripheral arterial disease, particularly after
endovascular intervention. Animal studies have shown that clopidogrel significantly inhibits coagulation activation. The
aim of this study was to determine whether combination of aspirin and clopidogrel affects thrombin-antithrombin III
and D-dimer in patients with intermittent claudication undergoing angioplasty, compared with aspirin alone.
Methods: This was a double blind, randomized placebo-controlled trial conducted in a vascular unit in a tertiary referral
center. One hundred thirty-two patients with intermittent claudication were randomized to clopidogrel and aspirin or
placebo and aspirin, with a loading dose 12 hours before endovascular intervention. D-dimer and thrombin-antithrom-
bin III (TAT) levels were measured using enzyme-linked immunosorbent assay at baseline, 1 hour before, and 1 hour, 24
hours, and 30 days after intervention in 103 patients who underwent endovascular intervention.
Results: There was a significant rise in D-dimer levels at 1 hour and 24 hours after angioplasty in both groups (placebo
group: 63.69, 141.45, 122.18 ng/mL; clopidogrel group: 103.79, 159.95, 134.69 ng/mL), but no difference between
the two groups (P  .514). Similarly there was a significant rise in TAT levels at 1 hour after angioplasty in both groups
(placebo group: 2.93, 6.16 g/L; clopidogrel group: 3.39, 5.27 g/L), with no significant difference between the two
groups (P  .746).
Conclusion: Endovascular intervention results in a significant increase in TAT and D-dimer. The addition of clopidogrel
to aspirin has no effect on TAT and D-dimer before or after endovascular intervention. (J Vasc Surg 2005;42:252-8.)Coagulation activation has been shown to be signifi-
cantly increased in patients with peripheral arterial occlusive
disease.1-6 This has been implicated in the increased risk of
this group of patients for cardiovascular, cerebrovascular,
and peripheral vascular events, and hence the significantly
increased risk of mortality compared with age-matched
controls.7-9 These risks are even higher at around the time
of endovascular or surgical intervention. Coagulation acti-
vation markers increase further after coronary10-12 and
peripheral endovascular intervention.13 It is unclear, how-
ever, whether this increase in response to intervention
contributes to the increased risk of periprocedural events or
whether medical intervention to reduce coagulation activa-
tion will translate into a reduced risk for such events.
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252Patients with peripheral arterial disease are routinely
administered antiplatelet treatment in the form of aspirin.
Clopidogrel is a prodrug metabolized in the liver to an
active compound that is an adenosine 5=-diphosphate
(ADP)-receptor antagonist, which mediates its antiplatelet
effect. Clopidogrel is increasingly used, particularly in com-
bination with aspirin, in high-risk patients. The benefits of
combination aspirin-clopidogrel in non-ST elevation myo-
cardial infarction14 and in patients undergoing coronary
stenting have been identified in randomized controlled
trials.15 These benefits are probably mediated through the
improved antiplatelet effect of the combination of drugs.
However, platelet ADP receptors have also recently
been shown to contribute to the initiation of intravascular
coagulation through rapid exposure of tissue factor,16
which is themajor initiator of coagulation. Furthermore, ex
vivo inhibition of the P2Y12-ADP receptor by clopidogrel
administration diminished rapid exposure of tissue factor in
mice.16 As early as 1994, Savi and colleagues17 had shown
that clopidogrel was able to inhibit platelet-induced tissue
factor expression in rats, whereas aspirin was ineffective.17
In separate studies, it was shown that clopidogrel signifi-
cantly inhibited shear-induced coagulation in rats whereas
aspirin did not,18 and that clopidogrel inhibited thrombus
formation in a stasis-induced venous thrombosis rat mod-
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observed with use of clopidogrel may be partly due to
inhibition of coagulation activation.
The aim of this study was to determine whether com-
bination aspirin-clopidogrel treatment has any affect on
coagulation activation in patients with intermittent claudi-
cation undergoing endovascular intervention. The antico-
agulation markers (thrombin-antithrombin III [TAT] and
D-dimer) measured were the secondary outcome measures
in a randomized controlled trial investigating the effect of
combination aspirin-clopidogrel treatment on platelet acti-
vation (primary outcome measure) in patients undergoing
endovascular intervention.20 The results of this study
showed that combination aspirin-clopidogrel reduces
platelet activation more effectively than aspirin alone in this
group of patients.
Fibrin D-dimer is a degradation product of cross-linked
fibrin that is brought about by plasmin. The latter is con-
verted from its precursor plasminogen by the action of
tissue plasminogen activator. TAT is a single, polypeptide
serum protein synthesized by the liver that forms the com-
plex with activated thrombin, destroying its enzymatic
activity. D-dimer and TAT complexes therefore serve as
markers of coagulation activation. Because platelet ADP
receptors contribute to intravascular coagulation through
rapid exposure of tissue factor, clopidogrel, which is an
ADP-receptor antagonist, may reduce coagulation activa-
tion.
METHODS
All patients between the ages of 18 and 80 years re-
ferred to the Vascular Unit of the Aberdeen Royal Infir-
mary with lifestyle-limiting claudication of the lower limbs
and evidence on duplex scanning of arterial stenosis or
occlusion in either the aortoiliac or femoropopliteal seg-
ments suitable for angioplasty were considered for partici-
pation in the study. Eligible participants were included if
they were able to provide informed consent and satisfied
inclusion and exclusion criteria (Table I). Patients were
recruited between March 2002 and January 2003.
The main outcome measure for the randomized con-
trolled trial was platelet activation on which the power
calculation was based and which has been published.20,21
Coagulation markers were the secondary outcome mea-
sures of the study.
Interventions. Patients were randomized to receive
either 75 mg clopidogrel and 75 mg aspirin daily for 30
days, with a loading dose of 300 mg clopidogrel adminis-
tered 12 hours before planned intervention, or 75 mg
aspirin and placebo daily, with a loading dose of placebo
administered 12 hours before intervention. A control
group receiving no antiplatelet medication was not in-
cluded in this study, as this was considered unethical. The
drugs were supplied in identical packs by the Trial Drugs
Pharmacy Department at Aberdeen Royal Infirmary.
Patients underwent digital subtraction angiography
followed by endovascular intervention. Endovascular pro-
cedures were performed by one of two experienced consul-tant interventional radiologists. Intravenous heparin
(3,000 to 5,000 units) was used in all procedures per-
formed. The dose given depended on the patient’s weight.
Blood samples were taken at baseline before clopi-
dogrel or placebo was administered, 1 hour before the
endovascular intervention, and then at 1 hour, 24 hours,
and 30 days after the endovascular intervention. Blood
samples were collected using a 21-gauge needle inserted
into an antecubital vein with the cuff applied to the upper
arm. The cuff was removed once the first trickle of blood
appeared into the first of two 1:10 3.2% sodium citrate
Vacutainers (Beckton Dickinson, Franklin Lakes, NJ). Ten
milliliters of blood collected in sodium citrate Vacutainers
was centrifuged at 3,000 rpm at 21°C for 10 minutes. The
serum was stored at –80°C until the enzyme-linked immu-
nosorbent assay (ELISA) was performed. An Enzygnost
TATmicro ELISA kit (Dade Behring, Marburg, Germany)
was used to measure TAT and a Dimertest Gold EIA kit
(AGEN, Brisbane, Australia) was used to measure
D-dimer.
Randomization. Pharmacists dispensed placebo or
active drug packs according to a computer-generated ran-
domization process that balanced the control and treat-
ment groups with respect to sex, diabetes mellitus, and
smoking status using a minimization method. The decision
to accept or reject participants was made and informed
consent obtained from participants before randomization,
ensuring allocation concealment. The code was held by the
Trial Drugs Pharmacy Department and was only revealed
to the researchers once recruitment, data collection, and
laboratory analyses were complete. Participants were en-
rolled by the first author (KC), and participants assigned
Table I. Patient inclusion and exclusion criteria
Inclusion criteria:
● Hemoglobin 10 g/dL
● Platelet count 150  109/L; normal
APTT/INR/fibrinogen
● Aspartate aminotransferase, alkaline phosphatase, gamma-
glutamyl transferase 3 times upper normal limit
● Serum creatinine 2 times upper normal limit
● Body mass index 33
● Age, 18 to 80 years
● No contraindication to aspirin or clopidogrel
Exclusion criteria
● History of hematologic malignancy
● Acute illness 14 days before randomization
● Transfusion of whole blood or red blood cells 14 days
before randomization
● Known or suspected drug or alcohol abuse
● Taking steroids, other drugs with antiplatelet effects (eg,
NSAIDs), warfarin or heparin
● History of bleeding diathesis or coagulopathy
● History of severe neutropenia (neutrophil count 1.8 
109/L)
● History of thrombocytopenia (platelet count 150 
109/L)
APTT, Activated partial thromboplastin time; INR, international normal-
ized ratio; NSAIDs, nonsteroidal anti-inflammatory drugs.and drug packs provided by the Trial Drugs Pharmacy
ipant
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blinded to treatment assignment for the duration of the
study. Full ethical approval for the study was granted by the
local ethics committee. Permission for Sanofi-Synthelabo
to supply clopidogrel for the purposes of the study was
obtained from the Medicines Control Agency.
Statistical analysis. All data analysis was carried out
according to pre-established analysis plans. Results are pre-
sented as mean values and 95% confidence intervals. Be-
tween subjects, analysis of variance (ANOVA) was used to
compare placebo and clopidogrel groups. P  0.05 was
accepted as statistically significant. Within subjects,
Fig 1. Flow of particANOVA was used to estimate treatment effect.RESULTS
Fig 1 shows the flow of participants through each stage.
BetweenMarch 2002 and January 2003, 132 patients were
recruited and randomized, 65 to placebo and 67 to the
clopidogrel group. Seven patients were excluded after ran-
domization because of failure to attend for angiography or
diagnosis of malignancy after randomization but before
administration of treatment. One hundred twenty-five pro-
ceeded to angiography, and 103 underwent vascular inter-
vention.
In 22 patients, endovascular intervention was deemed
s through the study.unfeasible or too risky, mainly because of a single patent calf
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proximal calf vessel disease, which substantially increased
the risk of intervention. After discussion and agreement,
angioplasty was not performed.
Forty-nine patients in the placebo group and 54 pa-
tients in the clopidogrel group underwent endovascular
intervention. The median ankle-brachial pressure index in
the affected limb in the placebo group was 0.63 and in the
clopidogrel group 0.65. Fifteen patients in the placebo
group and 16 in the clopidogrel group had treatment of the
aortoiliac segment disease, and 34 patients in the placebo
group and 37 in the clopidogrel group had femoropopliteal
segment disease treated. One patient in the clopidogrel
group had both iliac and femoropopliteal segment disease
treated. Stenting of the iliac segment was required in 13
patients in the placebo group and 15 in the clopidogrel
group. No stents were inserted in the femoropopliteal
segment.
None of these patients was lost to follow-up. Data from
103 patients who underwent endovascular intervention
were analyzed. All follow-up visits were completed by
March 2003.
Four patients in the placebo group stopped the trial
medication early because of rash (n 2), loss of medication
(n  1), or voluntarily (n  1). Seven patients in the
clopidogrel group stopped taking the trial medication early
because of the development of a rash (n  2), upper
gastrointestinal bleeding (n  1), epigastric pain (n  1),
ischemic stroke (n 1), loss of medication (n 1), and no
Table II. Baseline demographics and clinical characteristic
T
(n 
Males:females 10
Mean age (yrs) (range) 65.7
Smoking (%)
never smoked 8
ex-smoker 1 yr 55
ex-smoker 1 yr 24
smoker 45
Diabetes mellitus (%) 23
Mean serum cholesterol (mmol/L)* 3.9
Mean body mass index* 25.8
Median ankle-brachial pressure index (range) 0.64 (0
Intervention
None
Angiography only
Transluminal PTA
Subintimal PTA
Stenting
Site of disease treated
None
Aortoiliac segment
Femoropopliteal segment
Aortoiliac  fempop segments
PTA, Percutaneous transluminal angioplasty.
*Data are  standard deviation.apparent reason (n  1). Two patients failed to take theirloading dose on time and one patient was seen for the
30-day postintervention visit on day 38.
Analysis was on a modified intention-to-treat basis, and
results from all patients who underwent endovascular inter-
vention irrespective of compliance with trial medication
were analyzed. Patients who did not undergo endovascular
intervention were not included in the analysis. Data from all
103 patients who underwent endovascular intervention
were analyzed at all time intervals. Table II shows the
baseline demographics and clinical characteristics of the
patients in both groups, the type of intervention per-
formed, and the site of disease treated.
D-dimer. D-dimer levels at baseline were similar be-
tween the placebo group (89.33 ng/mL) and the clopi-
dogrel group (73.01 ng/mL) (P  .89). Fig 2 shows the
results of D-dimer levels in the placebo and clopidogrel
groups at different time-points in the study in the form of
box plots. The administration of the clopidogrel loading
dose did not have an affect on D-dimer levels, as shown by
the lack of any significant change in D-dimer levels in the
clopidogrel group at 1 hour before the intervention.
Percutaneous transluminal angioplasty had a significant
effect on D-dimer levels, however. At 1 hour after angio-
plasty, D-dimer levels were significantly elevated compared
with baseline in both the clopidogrel and placebo groups.
Similarly, D-dimer levels at 24 hours after angioplasty
remained significantly elevated compared with baseline in
both groups. The highest D-dimer levels were reached at 1
hour after angioplasty in both the clopidogrel and placebo
Claudicants (n  132)
)
Placebo group
(n  65)
Clopidogrel group
(n  67)
50:15 52:15
0) 65.4 (46-80) 66.1 (43-80)
3 (4.6) 5 (7.5)
27 (41.5) 28 (41.8)
13 (20.0) 11 (16.4)
22 (33.8) 23 (34.3)
11 (16.9) 12 (17.9)
3 3.68  2.23 4.15  2.02
26.1  3.9 25.5  4.1
.14) 0.63 (0.36-1.14) 0.65 (0.36-0.91)
3 4
13 9
29 33
10 6
10 15
16 13
15 16
34 37
0 1s
otal
132
2:30
(43-8
(6)
(42)
(18)
(34)
(17)
 2.1
 4.0
.36-1
7
22
62
16
25
29
31
71
1groups. By 30 days after angioplasty, D-dimer levels had
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placebo groups.
ANOVA showed no difference between the clopi-
dogrel and placebo groups (P  .514). Table III gives
results and 95% confidence intervals for D-dimer levels at
different time points in both groups.
Thrombin-antithrombin III. TAT levels at baseline
were similar between the placebo group (3.09 g/L) and
the clopidogrel group (3.33 g/L) (P  .92).
Fig 3 shows the results for TAT levels in the two groups
at the different time points in the form of box plots.
TAT levels at 12 hours after the administration of a
loading dose did not differ from baseline levels in both the
Fig 2. Box plots of D-dimer levels (ng/mL) in (a) the placebo
and aspirin group and (b) clopidogrel and aspirin group. The bars
represent median values, and the whiskers represent smallest and
largest values. The top of box is the 75th percentile, and the
bottom of box is the 25th percentile. PTA, Percutaneous translu-
minal angioplasty.placebo and clopidogrel groups; however, at 1 hour afterangioplasty, TAT levels were significantly elevated com-
pared with baseline in both groups. In the placebo group,
TAT levels remained significantly elevated even at 24 hours
after angioplasty. In the clopidogrel groups, although the
TAT levels were higher than baseline at 24 hours after
angioplasty, this was not statistically significant. At 30 days
after angioplasty, TAT levels were down to baseline levels in
both groups.
Between-subjects ANOVA showed no difference be-
tween the clopidogrel and placebo groups with regards to
TAT levels. Table IV shows the mean values as well as 95%
confidence intervals for these values.
Adverse events. Two patients in each group devel-
oped a skin rash and two in each group developed a
hematoma at the site of radiologic access that did not
require surgical intervention. The number of patients who
developed bruising at and around the site of access was
slightly higher in the clopidogrel group (25 vs 16), but the
difference between the two groups was not statistically
significant. Two patients in the clopidogrel group had an
ischemic stroke at day 7 and day 12 after intervention. One
of these patients had stopped taking all medication imme-
diately after the intervention, against medical advice. Me-
lena secondary to bleeding from multiple small gastric
ulcers developed in one patient. One patient in the clopi-
dogrel group became hypotensive immediately after the
intervention and was found to have a retroperitoneal hema-
toma. This did not require surgical intervention but re-
sulted in a 7-day delay in discharge from the hospital.
DISCUSSION
This study shows that endovascular intervention in
patients with intermittent claudication results in a signifi-
cant increase in D-dimer and TAT despite the administra-
tion of heparin during the procedure. The addition of
clopidogrel to aspirin does not affect coagulation activation
in these patients, neither does it prevent or reduce the
increase in coagulation activation observed after endovas-
Table III. Between subjects analysis of variance for D-
dimer levels*
Group
Time of
measurement Mean
95% CI
lower
bound
95% CI
upper
bound
Placebo Baseline 89.33 45.58 133.07
1 hr pre-PTA 63.69 48.39 79.00
1 hr post-PTA 141.45 98.59 184.29
24 hr post-PTA 122.18 81.61 162.75
30 day post-PTA 78.64 59.88 97.40
Clopidogrel Baseline 73.01 53.17 92.84
1 hr pre-PTA 103.79 50.48 157.10
1 hr post-PTA 159.95 84.72 235.19
24 hr post-PTA 134.69 74.88 194.51
30 day post-PTA 102.39 62.65 142.14
CI, confidence interval; PTA, percutaneous transluminal angioplasty.
Between subjects analysis of variance: P  0.514.
*Mean value for healthy controls: 26.1 ng/mL6.cular intervention.
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lial matrix molecules, leading to platelet adhesion and
aggregation and the formation of a primary hemostatic
plug. However, in addition to this function in hemostasis,
platelets also contribute to thrombin formation and fibrin
generation, not least through provision of anionic phos-
pholipid, which serves as a template for the construction of
the tenase and prothrombinase complexes.
Savi and colleagues17 first showed that clopidogrel was
able to inhibit platelet-induced tissue factor expression in
endothelial cells in rats, whereas aspirin was ineffective.
Fig 3. Box plots of thrombin-antithrombin III (TAT) levels
(g/L) in the (a) aspirin and placebo and (b) aspirin and clopi-
dogrel groups. The bars represent median values, and the whiskers
represent smallest and largest values. The top of box is the 75th
percentile, and the bottom of box is the 25th percentile. PTA,
Percutaneous transluminal angioplasty.Later on, clopidogrel was found to inhibit shear-inducedcoagulation in rat blood, but ticlopidine and aspirin did
not.18 Clopidogrel was also found to significantly inhibit ex
vivo thrombin generation triggered by low concentrations
of tissue factor in rat platelet-rich plasma,19 confirming the
close relationship between platelet activation and thrombin
generation leading to coagulation.
Only recently has it been recognized that platelet ADP
receptors contribute to the initiation of intravascular coagula-
tion.16 Under in vitro conditions, the P2Y12 and the P2Y1
ADP receptors were both found to be implicated in the
exposure of tissue factor whenwhole bloodwas activatedwith
collagen injection. Leon and colleagues16 also showed that ex
vivo inhibition of the ADP receptor by clopidogrel adminis-
tration diminished this rapid exposure of tissue factor. These
findings suggested that clopidogrel administration could re-
duce the level of coagulation activation in humans.
The combination of aspirin and clopidogrel, however,
did not appear to have any effect on coagulation parameters
(platelet-dependent thrombin generation, antithrombin
III, TAT III complex, prothrombin fragment 12) in
patients with nonvalvular atrial fibrillation.21 Similarly, no
effect was noted on coagulation activation markers when
clopidogrel was administered in addition to aspirin in pa-
tients with non-ST elevation acute coronary syndromes.22
Neither did clopidogrel have any effect on coagulation
markers (prothrombin fragment 12) in patients undergo-
ing elective coronary stenting.23
The results of our study support the findings of these
studies that clopidogrel has no effect on coagulation acti-
vation markers. This is contrary to what would be expected
given the demonstrated role of the ADP receptor in the
initiation of coagulation.16
There are various possible explanations for the results of
our study. Failure to showanydifferencewith clopidogrelmay
be because of the limited statistical power of the study, al-
though this is unlikely considering that similar findings have
been published in the context of atrial fibrillation, coronary
stenting, and non-ST-elevation myocardial infarction. Fur-
Table IV. Between subjects analysis of variance for
thrombin-antithrombin III levels*
Group
Time of
measurement Mean
95% CI
lower
bound
95% CI
upper
bound
Placebo Baseline 3.0864 2.5516 3.6211
1 hr pre-PTA 2.9280 2.4433 3.4127
1 hr post-PTA 6.1559 4.4435 7.7684
24 hr post-PTA 3.8088 3.1831 4.4345
30 day post-PTA 3.0984 2.6834 3.5134
Clopidogrel Baseline 3.3304 2.6192 4.0416
1 hr pre-PTA 3.3855 2.4993 4.2716
1 hr post-PTA 5.2695 3.7117 6.8273
24 hr post-PTA 4.7862 3.3511 6.2212
30 day post-PTA 2.9885 2.4945 3.4826
CI, confidence interval; PTA, percutaneous transluminal angioplasty.
Between subjects analysis of variance: P  .746.
*Mean value for healthy controls, 2.36 g/L6.thermore, our sample size was sufficient to showdifferences in
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markers during and after endovascular intervention.The com-
bination of clopidogrel and aspirin was significantly more
effective at inhibiting platelet function than aspirin alone in
this group of patients. The antiplatelet combination caused a
significant reduction in flow cytometrically measured platelet
P-selectin expression, fibrinogen binding, and ADP-stimu-
lated fibrinogen binding compared with aspirin alone. 20
The handling of the blood after collection may lead to
artificially elevated coagulation markers, thus limiting the
identification of any difference between the two groups.
Great care was taken to standardize blood withdrawal and
to process blood immediately after sampling to diminish
artifactual coagulation activation, and the subjects them-
selves acted as their own controls.
Another possible explanation for failure to show a
difference is that clopidogrel is a P2Y12 ADP receptor
antagonist and therefore fails to block the P2Y1 ADP
receptor. The latter has been shown to be involved in rapid
tissue factor exposure, and it is possible that this alternative
pathway, which remains unblocked, allows tissue factor
exposure and initiation of coagulation to continue despite
adequate inhibition of the P2Y12 ADP receptor.
CONCLUSION
Our results show that combining clopidogrel and aspi-
rin does not reduce the increased levels of TAT and D-
dimer in patients with intermittent claudication and does
not prevent the further increase in these coagulation mark-
ers seen after endovascular intervention in this group of
patients. Any clinical benefit observed with combination
treatment in this group of patients is therefore unlikely to
be mediated through inhibition of coagulation activation.
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